Modified ER-LBD Caspase-9 Kill Switch for Sustained Transgene Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell and gene therapy products lack effective control mechanisms, leading to safety concerns such as toxicity in subjects, necessitating improved methods for regulating and controlling these therapies.
Innovation Solution
A targeting construct is developed comprising a modified estrogen receptor ligand binding domain (ER-LBD) with specific amino acid substitutions and a caspase 9 domain, integrated into a STEL gene regulatory element, enabling a suicide-switch mechanism for controlled cell death through inducible transgene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cell and gene therapy products are administered to subjects, then therapeutic effects are achieved, but safety concerns such as toxicity occur due to lack of control mechanisms
Solution Approach 1:
The patent incorporates a suicide gene (e.g., caspase-9) and its inducer into the therapy product beforehand, establishing a pre-built safety control mechanism that can be activated later if needed, rather than adding control after toxicity occurs
Solution Approach 2:
The patent uses an intermediary substance (inducer such as tamoxifen or synthetic ligands) that mediates between the therapeutic product and the suicide gene activation, allowing controlled induction of cell death without direct contact between the therapy and the killing mechanism
2Object-affected harmful factors
If a suicide-switch mechanism is introduced to control cell therapy safety, then adverse events are mitigated, but the system complexity increases
Solution Approach 1:
The patent modifies parameters of the ER-LBD domain through specific amino acid substitutions (G400V, M543A, L544A, V595A) to alter the suicide gene's sensitivity and selectivity toward synthetic ligands, achieving better control with reduced complexity
Solution Approach 2:
The patent uses a well-characterized biological system (estrogen receptor ligand binding domain) as a template or copy to build the suicide-switch mechanism, leveraging existing knowledge to reduce development complexity while achieving desired safety control
3Reliability
If transgene expression is sustained after cell transformation, then kill switch functionality is maintained, but expression control becomes more difficult
Solution Approach 1:
The patent integrates the suicide gene under the control of a constitutive promoter (e.g., STEL gene regulatory element) that provides universal, sustained expression across different cell states and transformations, ensuring the kill switch remains functional regardless of cell differentiation or transformation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a safe and controlled mechanism for regulating cell therapies by allowing selective activation of caspase-9-mediated apoptosis using synthetic ligands, mitigating adverse events and enhancing safety.
Implementation Method 1
Estrogen receptor (ER) is a ligand-dependent transcription factor that binds endogenous hormone ligands such as estrogen and estradiol. Synthetic ligands that bind to ER have been developed for treating ER-positive cancers
Data Source
AI summary
Provided herein are targeting constructs for sustained transgene expression of inducible cell death systems that include mutants of estrogen receptor alpha ligand binding domain (ER-LBD). Also provided are methods for use of the same, such as inducing cell death in a cell.